Sorrento Therapeutics (OTC:SRNE) Stock, Earnings Estimates, EPS, And Revenue

Sorrento Therapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.

Earnings Date
Nov 8
EPS
$-0.200
Quarterly Revenue
$17.4M
Annual Revenue
(as of Jun 30)
$64.3M

Analyze the earnings history of Sorrento Therapeutics using advanced sorting and filters.

Data brought to you by Benzinga APIs

Sorrento Therapeutics (SRNE) Earnings Per Share

Quarterly Earnings Surprise Amount

Fiscal Quarter EndDate ReportedActual EPSEstimated EPSSurprise %
Sep 20212021-11-05$-0.40$-0.21-90.5 %
Jun 20212021-08-06$-0.57$-0.20-185.0 %
Mar 20212021-05-05$0.01$0.24-95.8 %
Jun 20202020-08-04$-0.36$-0.24-50.0 %

Sorrento Therapeutics (SRNE) Revenue

Quarterly Revenue Surprise Amount

Fiscal Quarter EndDate ReportedActual RevenueEstimated RevenueSurprise %
Sep 20212021-11-05$12.06M$10.21M18.1 %
Jun 20212021-08-06$13.51M$10.13M33.4 %
Mar 20212021-05-05$14.26M$17.25M-17.4 %
Jun 20202020-08-04$9.01M$7.90M14.0 %

FAQ

Q

When is Sorrento Therapeutics (OTCEM:SRNE) reporting earnings?

A

Sorrento Therapeutics ({quoteSymbol}) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 8, 2022 for Q3.

Q

What were the latest earnings per share (EPS) for Sorrento Therapeutics (OTCEM:SRNE)?

A

Sorrento Therapeutics ({quoteSymbol}) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 8, 2022 for Q3 and the Actual EPS was $-0.20, which missed the estimate of $0.00.

Q

What were Sorrento Therapeutics’s (OTCEM:SRNE) revenues?

A

Sorrento Therapeutics ({quoteSymbol}) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 8, 2022 for Q3 and the Actual EPS was {{actualEPS}}, which beat the estimate of {{estEPS}}.

Browse earnings estimates, EPS, and revenue on all stocks.